Published November 15, 2016
| Published
Patent
Open
Antibodies directed toward the HIV-1 GP120 CD4 binding site with increased potency and breadth
Abstract
Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) potent VRC01-like (PVL) antibodies targeted to gp120 having an amino acid substitution in the heavy chain at a residue in the anti-CD4 binding site PVL antibody that is equivalent to Phe43 in CD4 and an amino acid substitution in the light chain, these antibodies having improved potency and breadth.
Additional Information
Application title: Anti-hiv antibodies having increased potency and breadth. US Grant. Application number US13714398. Priority date 2011-07-25. Filing date 2012-12-13. Publication date 2016-11-15. Grant date 2016-11-15. Government Interests: This invention was made with government support under P01 A1081677-01, awarded by the National Institutes of Health. The government has certain rights in the invention. Parent Case Text: The present application claims priority to and the benefit of U.S. Provisional Application Ser. No. 61/570,173 filed on Dec. 13, 2011, and is continuation in part of U.S. patent application Ser. No. 13/558,312, filed Jul. 25, 2012, the entire contents of both of which are incorporated herein by reference.Attached Files
Published - US9493549.pdf
Files
US9493549.pdf
Files
(5.7 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:63a288c8a5b6c3b510fed472838d7568
|
5.7 MB | Preview Download |
Additional details
- Alternative title
- Anti-hiv antibodies having increased potency and breadth
- Eprint ID
- 82687
- Resolver ID
- CaltechAUTHORS:20171025-161147200
- P01 A1081677-01
- NIH
- Created
-
2017-10-25Created from EPrint's datestamp field
- Updated
-
2019-10-03Created from EPrint's last_modified field